9M 2023 Financial Performance

9M 2023: Business update Abilify Maintena continues market share gain Global LAI market & Abilify LAI franchise¹) share (quarterly USD & MS%) Global Abilify LAI franchise¹) revenue (DKKm) USDM 1,600 1,200 800 400 8 (%) 30 20 20 10 10 +11% CER DKK 2,164m +14% CER +7% CER +17% CER DKK 2,374m 0 2020 2021 2022 2023 Revenue Value market share % 9M 2022 9M 2023 United States Europe International Markets Abilify Maintena was approved by FDA in February 2013 and by the EU Commission in November 2013.1) Abilify LAI franchise refers to Abilify Maintena and Abilify Asimtufii combined. LAI: long-acting injectable (LAI) EVERY TWO MONTHS 960MG Abilify Asimtufii ONCE MONTHLY A> Abilify Maintena Abilify LAI franchise¹) delivering double-digit growth • • Growth driven by robust demand Strong performance in most markets, such as the U.S., Canada and Italy Outperforming the global LAI market growth and gain market share in key markets Abilify Asimtufii has been launched in the U.S. to further strengthen the Abilify LAI franchise

View entire presentation